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ARENA SOFTWARE ANDVALIDATINGTHE MODEL
Menn P, Sun J, Holle R
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OBJECTIVES: To develop a Markov model for an economic
evaluation of a hypothetical intervention in chronic obstructive
pulmonary disease (COPD), to implement it in TreeAge and
ARENA in order to ensure its technical validity and to compare
ease of implementation. METHODS: We used a 7-state Markov
model (disease stages I to IV according to GOLD classiﬁcation,
post-surgery, post-transplantation and death) with a time frame
of 60 years to assess incremental costs (€) and effects (life-years
gained, LYG). Applying identical assumptions regarding transi-
tions and costs, we ran Monte Carlo simulations with 10,000
patients for 100 replications in both packages. Additionally, we
calculated expected values for the TreeAge model. RESULTS: In
TreeAge, the simulation resulted in higher incremental costs and
effects compared to ARENA (p < 0.0001). Standard errors in
both packages were equal for effects, but slightly higher for costs
in ARENA. For the TreeAge model, averaged simulated values of
both costs and effects were close to the expected values, indicat-
ing adequate sample size. Run-time was slightly shorter in
ARENA. Yet determining cost-effectiveness values was more
convenient using TreeAge. CONCLUSION: Building a standard
Markov model for cost-effectiveness calculations appears more
comfortable in TreeAge. Useful tools for calculating and plotting
the results of an economic evaluation are available and can easily
be applied. In ARENA, users must implement these features
themselves, yet the user is more ﬂexible when classical Markov
assumptions no longer hold.
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OBJECTIVES: Direct preference elicitation is uncommon in
clinical trials of COPD treatments. Investigators have created an
algorithm that estimates EQ-5D preference weights from the St.
George’s Respiratory Questionnaire (SGRQ) to permit the
calculation of QALYs. METHODS: Using data from a placebo
controlled randomized trial comparing three regimens: 1) tiotro-
pium plus placebo; 2) tiotropium plus salmeterol; and 3) tiotro-
pium plus salmeterol/ﬂuticasone) in COPD, we examined the
validity of estimated EQ-5D scores from the SGRQ. RESULTS:
A total of 351 patients with complete SGRQ scores at each point
in the trial were included in the analysis. The mean values of the
SGRQ and the estimated EQ-5D revealed similar pattern across
the three treatments over time. A scatterplot of the SGRQ scores
versus the EQ-5D scores showed that although there was an
underlying linear relationship, it was somewhat “stepped” as the
conversion algorithm results in the estimation of the same
EQ-5D utility value for a number of SGRQ scores. Given that the
minimally clinical important difference (MCID) of the SGRQ is
4, it would be possiblethat one might lose an MCID response
when converting to the EQ-5D (whose MCID is 0.03). This was
not the case in 85% of the SGRQ MCID responders. Finally, to
see if any of the above made a difference statistically, the SGRQ
scores and the estimated EQ-5D scores were compared at the end
of the study (52 weeks). For the predicted mean EQ-5D utilities,
treatment arms 1 and 3 were signiﬁcantly different. However,
when using the SGRQ, treatment arms 1 and 3 and treatment
arms 1 and 2 were signiﬁcantly different. CONCLUSION: The
conversion algorithm was judged to be sufﬁcient. However, use
of the algorithm resulted in a reduction in discriminatory ability
of the estimated EQ-5D as compared to the SGRQ.
RESPIRATORY DISORDERS—Patient Reported Outcomes
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OBJECTIVES: Evaluate diagnostic validity of indirect methods
of compliance assessment (Gold standard: number of doses
applied per day) in COPD (Chronic Obstructive Pulmonary
Disease) patients with inhaled regular medication. METHODS:
Cohort study of 98 patients with follow up of sis months. Vari-
ables: age, gender, educational level, comorbidity, COPD staging
(by SEPAR recommendations), prescribed drugs, and indirect
methods for compliance assessment (Morisky-Green test, Batalla
test), and count of number of doses applied per day as gold
standard (electronic count or perforated pills number).
RESULTS: Predominace of males, with mean age of 69 years (CI
95% 67–72); low cultural level, 23% smokers (28 cigarrettes/day
[CI 95%, 26.73–30.67]) Overweight (Body Mass Index
29 kg/m2 [CI 95%, 29.1–30.1]). Seventy-ﬁve percent of patients
are in mild-moderate severity stage with predominance of mixed
respiratory pattern; FEV1 (mean) 53.99 (IC 95% 50.07–57.91).
A total of 1.67 exacerbations per year [IC 95%, 1.31–2.03].
Pharmacological treatment: inhaled anticholinergic 89.8%
patients inhaled beta2-adrenérgic 86.7% patients, inhaled corti-
costeroids 70.4% patients; xantins 16.3% patients, oxygen
therapy 5.1% patients; oral corticosteroids 1% patients, muco-
lytics 2% patients. Sixty-six percent patients (67.3%) completed
follow-up. Compílance prevalence: gold standard: 57.6%;
Morisky-Green test 50.8% sensibility 58%, speciﬁcity 67%, like-
lihood ratio for positive result 1.76; Batalla test 63.1%; sensibil-
ity 83%, speciﬁcity 70%, likelihood ratio for positive result 2.76.
When consider together both indirect METHODS: sensibility
50%, speciﬁcity 89%, likelihood ratio for positive result 4.54.
CONCLUSION: Indirect methods for compliance assessment are
valid and applicable in clinical follow-up of patients with COPD.
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OBJECTIVES: The objective of this study was to examine the
impact of salmeterol/ﬂuticasone propionate combination (SFC)
on the health related quality of life (HRQOL) of patients with
respiratory diseases. HRQOL data is not often collected when
examining the impact of treatment in Ireland eventhough
improving HRQOL is one of the main objectives of treatment of
chronic diseases. METHODS: This was a non-interventional,
observational cohort study that recruited 113 patients attending
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